Even though the ratio of SIGLEC1 to CD68 expression (SIGLEC1/CD68) correlated with tumor grade (Supplementary Fig. 1d), patients with high SIGLEC1/CD68 ratios had improved overall survival (Fig. 1a). The gene discussed is CD68; the disease is neoplasm.